Home > Financial Ratios > GLAND PHARMA
AD     Remove this Ad

GLAND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   EV/Core EBITDA(x) 16.1519.1713.5429.1926.12

What is the latest EV/Core EBITDA ratio of GLAND PHARMA ?

The latest EV/Core EBITDA ratio of GLAND PHARMA is 16.15 based on Mar2025 Consolidated results.
Year EV/Core EBITDA
Mar202516.15
Mar202419.17
Mar202313.54
Mar202229.19
Mar202126.12

How is EV/Core EBITDA of GLAND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2025 16.15
-15.75
Mar2024 19.17
41.58
Mar2023 13.54
-53.61
Mar2022 29.19
11.75
Mar2021 26.12 -

Other Financial Ratios of GLAND PHARMA


Compare EV/Core EBITDA ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹30,043.0 Cr 1.1% -1.2% 22.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹417,028.0 Cr 0.3% 9% 8.6% Stock Analytics
DIVIS LABORATORIES ₹170,237.0 Cr 1.9% 5.9% 12.6% Stock Analytics
TORRENT PHARMACEUTICALS ₹146,801.0 Cr 0.6% 9.5% 45% Stock Analytics
CIPLA ₹108,861.0 Cr 1.6% 1.8% -7.9% Stock Analytics
DR REDDYS LABORATORIES ₹107,435.0 Cr -1.5% 5.7% 14.5% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

1.1%

-1.2%

22.5%

SENSEX

-1.8%

-1.6%

7.3%


You may also like the below Video Courses